ClinicalTrials.gg
CompletedNCT02266511Updated Oct 17, 2014

Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride in Healthy Male Subjects

A Phase 1 interventional study of Flomax®, Norman II facility and Flomax®, Nishine facility in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-17.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Study summary

The objective of this study is to determine the bioequivalence of two batches of Flomax® 0.4 mg capsules in healthy male subjects. One is a commercial scale batch produced at the Nishine facility, and the other is a batch, of equal size, produced at the Norman II facility

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written informed consents, as evidenced by signature on an Form approved by the review board (IRB) following a full explanation of the nature and purpose of the study
  • Be a healthy male of any race between 18 and 40 years of age
  • Have a body weight within 10 % of normal for sex, height, and frame as specified by the Body Weight Nomogram for Inclusion/Exclusion Criteria
  • Have no abnormalities o the basis of medical history, physical examination, and vital signs with no significant orthostatic blood pressure change, which is defined as no more than a 20 mm Hg drop in systolic blood pressure on assuming and maintaining the standing position for 3 minutes after being supine for at least 5 minutes. There should be no clinically significant symptoms associated with the orthostatic blood pressure testing procedure
  • Have cardiovascular system that is within normal limits based on history, physical examination, and a 12-lead (ECG)
  • Have a negative test for ethanol by breathalyzer
  • Have the ability to understand the requirements of the study, agree to abide by the study restrictions, and agree to return for the required assessments

Exclusion criteria

Exclusion Criteria:

  • Require ambulatory assistance (e.g., canes or walkers)
  • Have a history of a "first dose hypotensive episode" upon starting therapy with an alpha-blocker
  • Have a history of a pathological fall (unintentional change in body position) during the last year occurring under circumstances in which normal homeostatic mechanisms would ordinarily maintain stability or syncope
  • Have any medical or laboratory abnormalities (liver function tests, blood urea nitrogen, and creatinine should not be outside the reference range for the clinical laboratory). Any subject who enters into the study with laboratory abnormalities must be approved by the Medical Monitor prior to enrollment
  • Have abnormal alpha-1-acid glycoprotein values (i.e., values greater than 120 mg/dL)
  • Have any history of acute angina attacks during the prior 6 months
  • Have any abnormality of the or a history of a documented myocardial infarction (electrocardiographic changes, serum enzymes increases, and hospitalization) during the prior 6 months, or evidence of any myocardial infarction on an ECG
  • Have a 's Functional Classification of Heart Failure Class I, II, III, or IV
  • Have a prior history of endocarditis
  • Use any prescription medications within 2 weeks of dosing, or over-the-counter concomitant therapies with the exception of vitamins, dietary supplements, and acetaminophen within 7 days of dosing
  • Have used an drug within 1 month (30 days) of the Screening Period visit
  • Donated blood within 1 month of entering study
  • Have a known history of any of the following:

    • renal disease (renal dysfunction; i.e., creatinine greater than or equal to 2.0 mg/dL)
    • Severe cardiovascular disease (coarctation of the aorta, severe cardiac failure, second or third degree heart block, or severe angina)
    • Pulmonary disease (chronic lung disease or emphysema of a degree that could cause functional abnormalities of the right heart)
  • Have acute illness (e.g., acute upper respiratory infection) within 2 weeks prior to the start of the study
  • Have any medical condition that might interfere with either the absorption, distribution, metabolism, or excretion of tamsulosin
  • Have a history of any illness or allergy that, in the opinion of the Investigator, might confound the results of the study or pose additional risk in administering Flomax® to the subject
  • Have a history of liver disease or any physical findings suggestive of liver disease
  • Have smoked within the last 3 months or be known as or be suspected as an alcohol abuser or illicit drug user within the past year, or have a positive urine drug screen
  • Exhibit, in the opinion of the Investigator, the signs or symptoms of an immunodeficiency syndrome, whether spontaneously acquired, congenital, or iatrogenic (These syndromes are characterized by unusual susceptibility to infection [bacterial, viral, or fungal], the occurrence of disease, and lymphoreticular )
  • Have calculated less than 90 mL/min based upon the following formula:

    • Creatinine Clearance = (140 - age in years) (weight in kg) / (72) (serum creatinine)
  • Have a history of cancer except for nonmelanoma skin cancer treated by excision
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Flomax®, Nishine facility followed by Flomax®, Norman II facility

    Drug: Flomax®, Norman II facility · Drug: Flomax®, Nishine facility

  • Experimental
    Sequence 2

    Flomax®, Norman II facility followed by Flomax®, Nishine facility

    Drug: Flomax®, Norman II facility · Drug: Flomax®, Nishine facility

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve of the analyte in plasma at different time points (AUC)

    Time frame: Up to 48 h after drug administration

  2. Maximum concentration of the analyte in plasma (Cmax)

    Time frame: Up to 48 h after drug administration

  3. Time to reach the maximum concentration of the analyte in plasma (tmax)

    Time frame: Up to 48 h after drug administration

  4. Elimination half-life (t1/2)

    Time frame: Up to 48 h after drug administration

  5. Terminal elimination rate constant of the analyte in plasma (λz)

    Time frame: Up to 48 h after drug administration

  6. Number of participants with clinically relevant changes in laboratory values

    Time frame: Up to day 3 after last drug administration

  7. Number of participants with clinically relevant changes in vital signs (heart rate, orthostatic blood pressure, weight, temperature, respiration rate)

    Time frame: Up to day 3 after last drug administration

  8. Number of participants with adverse events

    Time frame: Up to day 3 after last drug administration

  9. Number of participants with clinically relevant changes in ECG

    Time frame: Up to day 3 after last drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 1999 and a primary completion of Sep 1999. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2014
First posted
Oct 17, 2014
Start
Aug 1999
Primary completionActual
Sep 1999
Last update
Oct 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02266511
Responsible party
Sponsor
First posted
Oct 17, 2014
Start date
Aug 1999
Primary completion
Sep 1999
Last update
Oct 17, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion